TY  - JOUR
A1  - Dorochow, Erika
A1  - Köhm, Michaela
A1  - Hahnefeld, Lisa Katharina
A1  - Gurke, Robert
T1  - Metabolic profiling in rheumatoid arthritis, psoriatic arthritis, and psoriasis: elucidating pathogenesis, improving diagnosis, and monitoring disease activity
T2  - Journal of Personalized Medicine
N2  - Immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (Ps), represent autoinflammatory and autoimmune disorders, as well as conditions that have an overlap of both categories. Understanding the underlying pathogeneses, making diagnoses, and choosing individualized treatments remain challenging due to heterogeneous disease phenotypes and the lack of reliable biomarkers that drive the treatment choice. In this review, we provide an overview of the low-molecular-weight metabolites that might be employed as biomarkers for various applications, e.g., early diagnosis, disease activity monitoring, and treatment-response prediction, in RA, PsA, and Ps. The literature was evaluated, and putative biomarkers in different matrices were identified, categorized, and summarized. While some of these candidate biomarkers appeared to be disease-specific, others were shared across multiple IMIDs, indicating common underlying disease mechanisms. However, there is still a long way to go for their application in a routine clinical setting. We propose that studies integrating omics analyses of large patient cohorts from different IMIDs should be performed to further elucidate their pathomechanisms and treatment options. This could lead to the identification and validation of biomarkers that might be applied in the context of precision medicine to improve the clinical outcomes of these IMID patients.
KW  - biomarkers
KW  - precision medicine
KW  - metabolomics
KW  - lipidomics
KW  - psoriasis
KW  - arthritis
KW  - rheumatoid
KW  - psoriatic
KW  - immune-mediated inflammatory diseases
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/72048
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-720487
SN  - 2075-4426
N1  - This work was supported by the Deutsche Forschungsgemeinschaft Sonderforschungsbereich SFB 1039/Z01 “Krankheitsrelevante Signaltransduktion durch Fettsäurederivate und Sphingolipide” and by the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD).
VL  - 12
IS  - 6, art. 924
SP  - 1
EP  - 23
PB  - MDPI
CY  - Basel
ER  -